Treatments

*May 2024* Key takeaway: Amivantamab  combined with lazertinib significantly improved PFSl compared to osimertinib  in treatment-naïve patients with EGFR-mutant advanced non-small cell lung cancer, including those with high-risk features, establishing it as a promising new standard of care. Amivantamab (ami), an EGFR-MET bispecific antibody with immune cell-directing activity, combined with lazertinib…

*May 2024* Key Points: In patients with refractory EGFR-mutated advanced non–small cell lung cancer (NSCLC), subcutaneous amivantamab plus lazertinib was noninferior to intravenous (IV) amivantamab, as assessed by pharmacokinetics and objective response rate (ORR). Administration time was reduced from 2 to 5 hours with IV amivantamab to less than 5 minutes…

*May 2024* As targeted therapy gets more precise, the treatment paradigms shift, particularly for patients with non–small cell lung cancer (NSCLC). This patient population has seen substantial changes in standard of care as more nuance is added to the understanding of how resistance and mutations within the tumor are targeted.…

*June 2024* In this START HERE lung cancer webinar, Dr. Christina Baik, Associate Professor of Medicine at the University of Washington and Fred Hutchinson Cancer Center, provides valuable insights into priorities for newly diagnosed patients. Dr. Baik also discusses essential tools for managing disease progression and recurrence. Watch the program…

*April 2024* The addition of the selective MET TKI savolitinib (Orpathys) to osimertinib (Tagrisso) demonstrated consistent safety and higher clinical activity vs savolitinib plus placebo in patients with EGFR-mutated, MET-amplified advanced non–small cell lung cancer (NSCLC) whose disease had previously progressed on osimertinib, according to findings from a proteogenomic analysis presented at…

*April 2024* This is  a recorded event where a team of top oncologists discusses emerging concepts and best practices in non-small cell lung cancer (NSCLC). In this video, Dr. Lyudmila Bazhenova discusses toxicities associated with antibody-drug conjugate treatment. Watch video here.

*April 2024* Abstract Background Current standard of care treatment for patients with ≥15 brain metastases(BM) is whole brain radiation therapy(WBRT), despite poor neurocognitive outcomes. We analyzed our institutional experience of treating these patients with stereotactic radiosurgery(SRS), with the aim of evaluating safety, cognitive outcomes, and survival metrics. Methods Patients who…

*April 2024* Video: Dive into the forefront of precision oncology with Drs. Pasi Janne and Jyoti Patel, where they unravel the potential of HER3-directed antibody-drug conjugates (ADCs) in revolutionizing treatment for NSCLC. Discover the transformative potential of HER3-directed ADCs in overcoming resistance to EGFR-targeted TKI therapies. This program offers a…

*April 2024* “The rapidly evolving first-line treatment landscape for patients with metastatic EGFR mutant non-small cell lung cancer (NSCLC)” remains a “hot topic,” according to Eric K. Singhi, MD, assistant professor at the University of Texas MD Anderson Cancer Center. He and fellow “Leading Thoughts: Lung Cancer” panelists Maya Khalil, MD, thoracic…